Our immunoSEQ survey level assays are designed to sequence up to 40,000 rearranged TCR genes, or approximately 240 nanograms of purified T cell DNA. If T cells are rare in your sample, such as a tissue biopsy, tumor, or other complex mixture of … Continue reading
Adaptive TCR Co-Founders Receive $1 Million Grant from W.M. Keck Foundation for Human Immune Profiling Research
SEATTLE, April 8, 2011 — Adaptive TCR co-founders, Harlan Robins, Ph.D., and Chris Carlson, Ph.D., received a $1 million grant from the W.M. Keck Foundation to pursue an ambitious project to sequence DNA from the human immune system to shed … Continue reading
Adaptive TCR launches the immunoSEQ™ product line – visualizing the immune system with next-generation sequencing.
Seattle, WA – Adaptive TCR Technologies, a biotech firm based in Seattle, WA, announced today the release of its immunoSEQ™ profiling service and immunoSEQ Analyzer™ bioinformatics software platform. Together, these tools provide researchers and clinicians the ability to profile and … Continue reading
Seattle, WA September 3, 2010 — A new study published in Science Translational Medicine highlights the kind of important insight that can be gained from an application of the immunoSEQTM immune system profiling technology. The study was authored by Harlan … Continue reading
Seattle, WA — Dr. Harlan Robins, Fred Hutchinson Cancer Research Center, has been awarded a grant of $150,000 from the Life Science Discovery Fund for the development of high-throughput sequencing strategies aimed at T cell receptors. This competitive award represents … Continue reading